The "Inherited Retinal Disease - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Inherited Retinal Disease Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Inherited Retinal Disease market. A detailed picture of the Inherited Retinal Disease pipeline landscape is provided, which includes the disease overview and Inherited Retinal Disease treatment guidelines.
The assessment part of the report embraces in-depth Inherited Retinal Disease commercial assessment and clinical assessment of the Inherited Retinal Disease pipeline products from the pre-clinical developmental phase to the marketed phase.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Inherited Retinal Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
All of the companies that are developing therapies for the treatment of Inherited Retinal Disease with aggregate therapies developed by each company for the same.
Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Inherited Retinal Disease treatment.
Inherited Retinal Disease key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Inherited Retinal Disease market.
Scope of the Report
The Inherited Retinal Disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Inherited Retinal Disease across the complete product development cycle, including all clinical and nonclinical stages.
It comprises of detailed profiles of Inherited Retinal Disease therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
Detailed Inherited Retinal Disease research and development progress and trial details, results wherever available, are also included in the pipeline study.
Coverage of dormant and discontinued pipeline projects along with the reasons if available across Inherited Retinal Disease.
Key Topics Covered
1. Report Introduction
2. Inherited Retinal Disease
2.3. Inherited Retinal Disease Symptoms
2.6. Inherited Retinal Disease Diagnosis
2.6.1. Diagnostic Guidelines
3. Inherited Retinal Disease Current Treatment Patterns
3.1. Inherited Retinal Disease Treatment Guidelines
4. Inherited Retinal Disease - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Inherited Retinal Disease companies collaborations, Licensing, Acquisition - Deal Value Trends
184.108.40.206. Assessment Summary
4.1.2. Inherited Retinal Disease Collaboration Deals
220.127.116.11. Company-Company Collaborations (Licensing / Partnering) Analysis
18.104.22.168. Company-University Collaborations (Licensing / Partnering) Analysis
22.214.171.124. Inherited Retinal Disease Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
126.96.36.199. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
188.8.131.52. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
184.108.40.206. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
220.127.116.11. Assessment by Stage and MOA
5.1.6. Assessment by Target
18.104.22.168. Assessment by Stage and Target
6. Inherited Retinal Disease Late Stage Products (Phase-III)
7. Inherited Retinal Disease Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Inherited Retinal Disease Discontinued Products
13. Inherited Retinal Disease Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
22.214.171.124. Product Overview
126.96.36.199. Mechanism of Action
13.1.2. Research and Development
188.8.131.52. Clinical Studies
13.1.3. Product Development Activities
184.108.40.206. Patent Detail
13.1.4. Tabulated Product Summary
220.127.116.11. General Description Table
14. Inherited Retinal Disease Key Companies
15. Inherited Retinal Disease Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Inherited Retinal Disease Unmet Needs
18. Inherited Retinal Disease Future Perspectives
19. Inherited Retinal Disease Analyst Review
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ld1fu5
View source version on businesswire.com: https://www.businesswire.com/news/home/20200703005047/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900